心血管補綴装置の世界市場-2023年～2030年

市場概要

心血管補綴装置の世界市場は、2022年に153億米ドルに達し、2023～2030年の予測期間中にCAGR 8.4％で成長し、2030年には289億米ドルに達すると予測されています。

心血管補綴装置は、人間の心臓の部品の機能を模倣したものです。これらの装置は、故障を修復したり、損傷した弁や組織を修復するために人体内で交換されます。人工心臓は一方向の血流を維持することで本来の弁の機能を再現するように設計されており、使用される材料は寿命があるもの抗凝固性でなければならないです。

人工心臓は、心臓、動脈、静脈などの心臓血管系の一部を置換または補助する埋め込み式または外付けの装置です。心血管補綴装置は、ほとんどの患者において生存率を改善し、生活の質を著しく向上させる。アボット・ラボラトリーズ、ボストン・サイエンティフィック、メドトロニックなど、その他の主要企業がこの市場で積極的に活動しています。

市場力学

心不全発生率の増加が市場成長を後押し

心不全の発生率の増加が市場成長を後押しする大きな役割を果たしています。多くの人々が心臓発作や心不全に悩まされており、それがインプラントの設置率を高めています。心不全は多くの人々に影響を及ぼす大きな問題です。例えば、米国心不全学会によると、年間96万人が新たに心不全を発症しています。毎年約3,770万人が入院しています。このように、心不全患者の発生率の増加が市場の成長を拡大しています。

老年人口の増加が市場成長を促進

老年人口の増加が市場成長の原動力となっています。加齢は心臓の機能に影響を及ぼす主要因の一つです。加齢が進むと心臓機能に悪影響が出る。加齢は心臓や血管に変化を引き起こす可能性があります。

例えば、AHAジャーナルによると、70歳以上の70％がCVDを発症すると推定されています。45歳以上の成人の14.2％が冠動脈性心疾患（CHD）、脳卒中、またはその両方に罹患していると報告されています。したがって、高齢者人口の増加は市場の成長を拡大させると思われます。

移植治療の高コストが市場成長を妨げる

移植治療にかかるコストが高いことが市場成長の妨げになる可能性があります。手術の複雑化に伴い、植え込みに関連する手術の治療費が増加しています。例えば、米国におけるペースメーカー手術の平均費用は2,000～2,500米ドルです。

COVID-19の影響分析

COVID-19の流行は心血管補綴装置に大きな影響を与え、多くの国に前例のない課題を突きつけています。外科手術の遅れや手術の延期、患者が病院に近づくことへの恐怖が、心血管補綴装置の使用への影響を示しています。その結果、COVID-19パンデミックの間、心血管補綴装置の成長は著しく低下しました。

ロシア・ウクライナ紛争影響分析

ロシアとウクライナの紛争は、この地域の主要な市場プレーヤーの数が少ないため、心血管補綴装置への影響は中程度と推定されます。しかし、原材料の輸出入の影響は、予測期間中、心血管補綴装置の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 心血管疾患の発生率の増加
    • 肥満患者の増加
  • 抑制要因
    • 機器に伴う合併症
  • 機会
    • 治療法の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 製品タイプ別

• ペースメーカー
• 植込み型心臓弁
• ステント
• その他

第8章 エンドユーザー別

• 病院
• クリニック／心臓センター
• 外来手術センター
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東およびアフリカ
  • 主な地域別ダイナミクス

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Abbott Laboratories
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Artivion, Inc
• Biotronik
• MicroPort Scientific Corporation
• JC Medical, Inc
• Boston Scientific
• Pacetronix
• Meril Life Sciences Pvt. Ltd
• Medtronic
• Lepu Medical Technology Co. Ltd

第12章 付録

Market Overview

Global Cardiovascular Prosthetic Device Market reached US$ 15.3 billion in 2022 and is expected to reach US$ 28.9 billion by 2030 growing with a CAGR of 8.4% during the forecast period 2023-2030.

A cardiovascular prosthetic device mimics the functions of the parts of the human heart. These devices are replaced in the human body in order to repair the malfunction or to repair the damaged valves or tissues. The cardiac prosthesis is designed to replicate the function of native valves by maintaining unidirectional blood flow, and the material that is used should be anticoagulant although life.

Cardiovascular prosthetic devices are implantable or external devices that replace or assist parts of the cardiovascular system, such as the heart, arteries, or veins. Prosthetic cardiac devices improve survival and significantly increase the quality of life in most patients. Significant key players like Abbott Laboratories, Boston Scientific, Medtronic, among others are actively operating in the market.

Market Dynamics

An Increase in the Incidence of Heart Failure is Boosting the Market Growth

An increase in the incidence of heart failure is playing a major role in boosting market growth. A large number of people are suffering from heart strokes and heart failure,which is increasing the rate of implantations. Heart failure is a major problem affecting many people. For instance, according tothe Heart Failure Society of America, 960,000 new heart failure cases annually. About 37.7 million people are hospitalized each year. Thus, the increase in the incidence of heart failure patients is expanding the market growth.

An Increase in the Geriatric Population is Fueling the Market Growth

The increase in the incidence of the geriatric populationis fueling the growth of the market. Aging is one of the major factors which shows the influence on the functioning of the heart properly. Heart function gets adversely affected as age increases. Aging can cause changes in the heart and blood vessels.

For instance, according to AHA Journals, it is estimated that 70% of people over 70 years old will develop CVD. 14.2% of adults aged 45 years and older reported having coronary heart disease (CHD), a stroke, or both. Thus increase in the number of aged population will expand the market growth.

High Cost of the Implantation Treatments Will Hamper the Market Growth

The high cost of the implantation treatments can hamper market growth. There is an increased cost for the treatments of surgeries related to implantation due to the increase in the complexity of the surgery. For instance, the average cost of pacemaker surgery in the US ranges between US$2,000- US$ 2,500.

COVID-19 Impact Analysis

The COVID-19 pandemic epidemic has had a significant influence on cardiovascular prosthetic devices, posing unprecedented challenges to many countries. The delayed surgical procedures and postponements of the surgeries, and the fear of patients approaching hospitals have shown the impact on the usage of cardiovascular prosthetic devices. This resulted in a significant decline in the cardiovascular prosthetic device growth during the COVID-19 pandemic.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the cardiovascular prosthetic device, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the cardiovascular prosthetic device growth over the forecast period.

Segment Analysis

The cardiovascular prosthetic device is segmented based on product type and end user.

The Implanted Heart Valve Segment Accounts for Approximately 23.8% of the Cardiovascular Prosthetic Device Share

An implanted heart valve is a one-way valve implanted into a person's heart to replace a heart valve that is not functioning properly. Due to the increase in the number of congenital heart valve diseases, implanted heart valve segment holds the highest market share.

According to texasheart.org, in the United States, surgeons perform about 106,000 heart valve operations each year. Each year approximately 40,000 babies are born in the United States with a congenital heart defect. Thus the above factors are influencing the segment to lead the market.

Geographical Analysis

Asia Pacific region accounted for Approximately 21.3% of the Market Share Owing to Technological Advancements

The rise in technological advancements and innovation of new devices is boosting the market share in Asia-Pacific region. A number of clinical trials and approvals have been taking place in this region in order to introduce a number of treatment methods and reduce mortality inthe region.

For instance, on 19 April 2022, Translumina announced the launch of the Vivo Isar dual-drug polymer-free coated stent in various international markets, including Europe and Asia-Pacific regions. Thus, the increase in technological advancements and new innovations is raising the growth of the market.

Competitive Landscape

The major global players in the cardiovascular prosthetic device market include: Abbott Laboratories, Boston Scientific Corporation, Lepu Medical Technology Co. Ltd, Medtronic Inc, Biotronik, Meril Life Sciences Pvt. Ltd, Pacetronix, MicroPort Scientific Corporation, Artivion, Inc, and JC Medical, Inc among others.

Why Purchase the Report?

• To visualize the cardiovascular prosthetic device segmentation based on product type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cardiovascular prosthetic device market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The cardiovascular prosthetic device report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by End-User
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. An increase in the incidence of cardiovascular diseases
    • 4.1.1.2. Increase in the number of obese patients
  • 4.1.2. Restraints
    • 4.1.2.1. Complications associated with the devices
  • 4.1.3. Opportunity
    • 4.1.3.1. Increased number of treatments
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. ByProduct Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Pacemakers
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Implanted Heart Valves
• 7.4. Stents
• 7.5. Others

8. ByEnd User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Clinics/Cardiac Centers
• 8.4. Ambulatory Surgical Centers
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Spain
    • 9.3.5.5. Italy
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan

Australia

• 9.5.5.4. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Abbott Laboratories
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Artivion, Inc
• 11.3. Biotronik
• 11.4. MicroPort Scientific Corporation
• 11.5. JC Medical, Inc
• 11.6. Boston Scientific
• 11.7. Pacetronix
• 11.8. Meril Life Sciences Pvt. Ltd
• 11.9. Medtronic
• 11.10. Lepu Medical Technology Co. Ltd

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us